Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lidocaine and dexmedetomidine effects on TNF-alpha after laparoscopic cholecystectomy
IRCT20190325043107N59Phase 3Completed
- Sponsor
- Tabriz University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lidocaine and dexmedetomidine in cholelithiasis (4 arms), sponsored by Tabriz University of Medical Sciences. Primary endpoint: Tumor necrosis factor alpha. Started Sep 2025; status: completed.
02
Drugs
lidocainedexmedetomidine
03
Conditions
cholelithiasis
Beyond the preview
Go deeper on IRCT20190325043107N59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190325043107N59.